The integration of artificial intelligence (AI) in protein design presents unparalleled opportunities for innovation in bioengineering and biotechnology. However, it also raises significant biosecurity concerns. This review examines the changing landscape of bioweapon risks, the dual-use potential of AI-driven bioengineering tools, and the necessary safeguards to prevent misuse while fostering innovation. It highlights emerging policy frameworks, technical safeguards, and community responses aimed at mitigating risks and enabling responsible development and application of AI in protein design.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11835847 | PMC |
| http://dx.doi.org/10.3389/fbioe.2025.1537471 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SubtiToolKit: a bioengineering kit for Bacillus subtilis and Gram-positive bacteria.
Trends Biotechnol
March 2025
Department of Bioengineering, Imperial College London, London, UK; Imperial College Centre for Synthetic Biology, Imperial College London, London, UK.
Building DNA constructs of increasing complexity is key to synthetic biology. Golden Gate (GG) methods led to the creation of cloning toolkits - collections of modular standardized DNA parts hosted on hierarchic plasmids, developed for yeast, plants, Gram-negative bacteria, and human cells. However, Gram-positive bacteria have been neglected.
View Article and Find Full Text PDFBispecific antibody therapy for lymphoma.
Best Pract Res Clin Haematol
December 2024
330 Brookline Ave, Boston, MA, 02215, USA. Electronic address:
The rapid development of novel therapeutics in B-cell Non-Hodgkin's lymphoma (B-NHL) over the past decade has presented a critical inflection point for the field. Bispecific antibodies are one such therapeutic class emerging as an effective, off-the-shelf option for B-NHL. In this review, we focus primarily on Diffuse Large B-cell Lymphoma (DLBCL), highlighting the evolution, comparison, tolerability, ongoing challenges, and future potential of bispecific antibodies that are currently approved or in clinical trials for B-NHL.
View Article and Find Full Text PDFDesigning of multi-valent epitope vaccine displaying interactions with diverse HLA alleles against Candida auris using immuno-informatics.
J Genet Eng Biotechnol
March 2025
Centre for Bioinformatics, M.D. University, Rohtak, Haryana, India. Electronic address:
The emergence of multidrug resistanceagainst several antifungal drugs and the absence of alternate therapy limits the treatment choices leading to the spread of Candida auris infections, especially inimmunocompromised patients. This work aims to construct the multi-epitope vaccine using an immuno-informatics approachdue to the lack of efficient treatments for C. auris.
View Article and Find Full Text PDFHigh-throughput screening of natural antiviral drug candidates against white spot syndrome virus targeting VP28 in Penaeus monodon: Computational drug design approaches.
J Genet Eng Biotechnol
March 2025
Department of Biotechnology and Genetic Engineering, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh. Electronic address:
The white spot syndrome virus (WSSV), considered the deadliest pathogen impacting Penaeid shrimp (Penaeus monodon), remains worrisome for the global shrimp industry due to its extreme virulence and mortality rate of up to 100%. To date, there has been no breakthrough in effective antivirals or vaccines that can mitigate the financial damage caused by the pathogen. The distinctive structure of VP28 facilitates its role as a trimer, serving as the primary envelope protein of WSSV.
View Article and Find Full Text PDFGPR171 restrains intestinal inflammation by suppressing FABP5-mediated Th17 cell differentiation and lipid metabolism.
Gut
March 2025
Department of Gastroenterology, Shanghai Tenth People's Hospital, Shanghai, China
Background: GPR171 suppresses T cell immune responses involved in antitumour immunity, while its role in inflammatory bowel disease (IBD) pathogenesis remains unclear.
Objective: We aimed to investigate the role of GPR171 in modulating CD4 T cell effector functions in IBD and evaluate its therapeutic potential.
Design: We analysed GPR171 expression in colon biopsies and peripheral blood samples from patients with IBD and assessed the impact of GPR171 on CD4 T cell differentiation through administration of its endogenous ligand (BigLEN).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!